AI-Sight

London, United Kingdom

AI Sight Limited delivers next-generation AI-powered diabetic eye screening to enhance accuracy, speed, and accessibility across healthcare systems. The company’s intelligent screening platform leverages advanced algorithms to detect diabetic retinopathy early, supporting clinicians in identifying patients at risk of sight loss. By integrating with existing retinal imaging devices and medical records, the system reduces manual workload, increases productivity by up to fourfold, and enables cost and time savings. Backed by clinical trial data and a team of world-leading ophthalmology experts, AI Sight provides a flexible, camera-agnostic solution that supports both routine screening and clinical research.